References
- Ho KY, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs. 1988;36(1):67–82.
- Parkes JD. Bromocriptine in the treatment of parkinsonism. Drugs. 1979;17(5):365–382.
- Kars M, Souverein PC, Herings RMC, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94(8):2729–2734.
- Hurault-Delarue C, Montastruc JL, Beau AB, et al. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014;290(2):263–270.
- Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol. 1972;114(6):822–828.
- Mathiesen L, Mose T, Mørck TJ, et al. Quality assessment of a placental perfusion protocol. Reprod Toxicol. 2010;30(1):138–146.
- Hutson JR, Garcia-Bournissen F, Davis A, et al. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther. 2011;90(1):67–76.
- Huang H, Wang J, Li Q, et al. Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. J Matern Fetal Neonatal Med. 2017;30(11):1288–1292.
- Karttunen V, Sahlman H, Repo JK, et al. Criteria and challenges of the human placental perfusion – data from a large series of perfusions. Toxicol In Vitro. 2015;29(7):1482–1491.
- Friis ML, Grøn U, Larsen NE, et al. Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson’s disease. Eur J Clin Pharmacol. 1979;15(4):275–280.
- Challier JC, D’Athis P, Guerre-Millo M, et al. Flow-dependent transfer of antipyrine in the human placenta in vitro. Reprod Nutr Dev. 1983;23(1):41–50.
- Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43(8):487–514.
- Nekhayeva IA, Nanovskaya TN, Pentel PR, et al. Effects of nicotine-specific antibodies, Nic311 and NIC-IgG, on the transfer of nicotine across the human placenta. Biochem Pharmacol. 2005;70(11):1664–1672.
- Berveiller P, Vinot C, Mir O, et al. Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. Am J Obstet Gynecol. 2012;207(6):514.e1–514.e7.
- Al-Enazy S, Ali S, Albekairi N, et al. Placental control of drug delivery. Adv Drug Deliv Rev. 2017;116:63–72.
- Vautier S, Milane A, Fernandez C, et al. Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model. Neurosci Lett. 2008;442(1):19–23.
- Mori M, Ishikawa G, Luo SS, et al. The cytotrophoblast layer of human chorionic villi becomes thinner but maintains its structural integrity during gestation. Biol Reprod. 2007;76(1):164–172.
- Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr. 1987;65(17):823–827.
- Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA. 1982;247(11):1589–1591.
- Shibli-Rahhal A, Schlechte J. Hyperprolactinemia and infertility. Endocrinol Metab Clin North Am. 2011;40(4):837–846.
- Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205–RR213.